Vimarsana
Biggest News Aggregation in the World

Page 30 - Device Regulation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Device Regulation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Device Regulation Today - Breaking & Trending Today

DOST-PNRI welcomes House panel's passage of bill creating atomic commission – Manila Bulletin - Vimarsana News

DOST-PNRI welcomes House panel's passage of bill creating atomic commission – Manila Bulletin

(Photo from the Philippine Nuclear Research Institute) “The Committee recently approved the substitute bill for the Comprehensive Atomic Regulation Act, consolidating 13 House bills in support of the measure,” it said in a statement on Friday, May 28. The substitute bill was approved by the House panel, chaired by ACT-CIS partylist Rep. Eric Go Yap during its meeting on May 12. House Committee on Appropriations meeting on May 12, 2021 (from DOST-PNRI) The DOST-PNRI noted that during the panel meeting, DOST Secretary Fortunato “Boy” T. de la Peña rallied behind the creation of an i...

Source: mb.com.ph
Henry Schein Reports Record First-Quarter 2021 Financial Results from Continuing Operations - Vimarsana News

Henry Schein Reports Record First-Quarter 2021 Financial Results from Continuing Operations

Published: May 04, 2021 Total net sales of $2.9 billion up 20.4% versus prior year GAAP diluted EPS from continuing operations of $1.16 versus prior-year GAAP diluted EPS from continuing operations of $0.91 Non-GAAP diluted EPS from continuing operations of $1.24 versus prior-year non-GAAP diluted EPS from continuing operations of $0.94 Reflecting strong first-quarter results, the Company raises guidance for 2021 non-GAAP diluted EPS from continuing operations to be at or above $3.70 Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based...

Time to build upon the momentum - Vimarsana News

Time to build upon the momentum

Today's Medical Developments Departments - Editor’s Letter COVID-19 highlighted U.S. manufacturing’s strengths and ingenuity – pivoting to testing swabs, PPE, and ventilator production. The pandemic also highlighted some weaknesses – reliance on international supply chains caused production shocks and disruptions. This is still a problem in some areas, such as microchip shortages after manufacturers misread, or simply missed, the pandemic-driven demand for microchips for smartphones, gaming consoles, PCs for work from home, and IT infrastructure upgrades. This intersection between man...

Voice Prosthesis Devices And Equipment Global Market Report 2021: COVID 19 Impact and Recovery to 2030 - Vimarsana News

Voice Prosthesis Devices And Equipment Global Market Report 2021: COVID 19 Impact and Recovery to 2030

Share: New York, May 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Voice Prosthesis Devices And Equipment Global Market Report 2021: COVID 19 Impact and Recovery to 2030" - https://www.reportlinker.com/p06067870/?utm_source=GNW Kg. The global voice prosthesis devices and equipment market is expected to grow from $0.45 billion in 2020 to $0.5 billion in 2021 at a compound annual growth rate (CAGR) of 11.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive ...

WuXi AppTec Reports Record First-Quarter 2021 Results - Vimarsana News

WuXi AppTec Reports Record First-Quarter 2021 Results

Net Profit Attributable to Owners of the Company Up 394.9% Year-over-Year to RMB1.50 Billion Diluted EPS Up 369.2% Year-Over-Year to RMB0.61 Adjusted Diluted Non-IFRS EPS Up 52.0% Year-Over-Year to RMB0.38 [1] SHANGHAI, April 29, 2021 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, announces its unaudited financial results for ...